Use of mometasone furoate for treating airway passage and lung diseases
First Claim
1. A method of treating a corticosteroid-responsive disease of the upper, or lower airway passages or of the lungs in patients afflicted with said disease, which comprises administering once-a-day to the surfaces of said passages or lungs of said patients a substantially non-systematically bioavailable amount of aerosolized particles of mometasone furoate effective for treating said disease.
1 Assignment
0 Petitions
Accused Products
Abstract
The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
3 Citations
29 Claims
- 1. A method of treating a corticosteroid-responsive disease of the upper, or lower airway passages or of the lungs in patients afflicted with said disease, which comprises administering once-a-day to the surfaces of said passages or lungs of said patients a substantially non-systematically bioavailable amount of aerosolized particles of mometasone furoate effective for treating said disease.
- 5. A method of treating allergic or non-allergic rhinitis in patients afflicted with said rhinitis which comprises administering once-a-day to the surfaces of the upper airway passages of said patients an amount of aerosolized particles of mometasone furoate effective to maximize topically treating said rhinitis in the upper airway passages while simultaneously substantially minimizing systemic bioavailability thereof.
- 9. A method of treating allergic and/or inflammatory diseases of the lower airway passages and/or lung in patients afflicted with at least one of said diseases which comprises administering once-a-day via oral administration to the surfaces of the upper and lower airway passages of said patients an amount of mometasone furoate effective to maximize topically treating said allergic and/or inflammatory diseases in the lower airway passage and/or lungs while simultaneously substantially minimizing the systemic bioavailability thereof.
- 18. A method of treating asthma in a patient afflicted with asthma which comprises administering once-a-day to the surfaces of the lower airway passages and lungs of the patient an amount of aerosolized particles of mometasone furoate effective to maximize treating asthma in the lower airway passages and lungs while simultaneously substantially minimizing systemic bioavailability thereof.
- 25. A method of producing a rapid onset of action in treating asthma in patients afflicted with asthma which comprises administering via oral inhalation to the lower airway passages and lungs of said patients a non-systematically bioavailable amount of aerosolized particles of mometsone furoate effective for producing said accelerated onset of action.
Specification